The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1701
April 29, 2024
View Complete Issue         Table of Contents 2019 
Resmetirom (Rezdiffra) for Metabolic Dysfunction-Associated Steatohepatitis
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Resmetirom (Rezdiffra) for Metabolic Dysfunction-Associated Steatohepatitis
April 29, 2024 (Issue: 1701)
Resmetirom (Rezdiffra – Madrigal), a thyroid hormone receptor-beta agonist, has received accelerated approval from the FDA for treatment of noncirrhotic nonalcoholic steatohepatitis (NASH) with moderate to advanced fibrosis in adults. NASH has...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Resmetirom (Rezdiffra) for Metabolic Dysfunction-Associated Steatohepatitis
Article code: 1701a
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.